The stock of Krystal Biotech Inc (NASDAQ:KRYS) last traded at $132.09, up 1.59% from the previous session.
KRYS stock price is now -9.03% away from the 50-day moving average and -21.13% away from the 200-day moving average. The market capitalization of the company currently stands at $3.82B.
With the price target of $245, Jefferies recently initiated with Buy rating for Krystal Biotech Inc (NASDAQ: KRYS). On August 06, 2024, Citigroup Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock increasing its target price from $195 to quote $204, while ‘Goldman’ rates the stock as ‘Buy’
In other news, Krishnan Suma, President, R&D sold 25,000 shares of the company’s stock on Mar 13 ’25. The stock was sold for $4,444,763 at an average price of $177.79. Upon completion of the transaction, the President, R&D now directly owns 1,533,056 shares in the company, valued at $202.5 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 13 ’25, President, R&D Krishnan Suma sold 25,000 shares of the business’s stock. A total of $4,444,761 was realized by selling the stock at an average price of $177.79. This leaves the insider owning 1,463,711 shares of the company worth $193.34 million. A total of 14.14% of the company’s stock is owned by insiders.
During the past 12 months, Krystal Biotech Inc has had a low of $122.80 and a high of $219.34. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 9.65, and a quick ratio of 9.27. According to the stock market information, the enterprise value for the company is $3210042624, which is based on a 31.81 price-to-earnings ratio, a 0.52 price-to-earnings-growth ratio, and a beta of 0.66. The fifty day moving average price for KRYS is $145.2056 and a two-hundred day moving average price translates $167.47763 for the stock.
The latest earnings results from Krystal Biotech Inc (NASDAQ: KRYS) was released for 2025-03-31. The net profit margin was 37.18% and return on equity was 13.90% for KRYS. The company reported revenue of $88.18 million for the quarter, compared to $45.25 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 94.88 percent. For the current quarter, analysts expect KRYS to generate $95.41M in revenue.
